在癌症患者中延长阿哌沙班用于静脉血栓栓塞症二级预防:EVE试验
EVE试验是一项随机双盲研究,在已完成6至12个月抗凝治疗的癌症相关静脉血栓栓塞症(VTE)患者中,比较阿哌沙班2.5 mg与5 mg每日两次再治疗12个月的效果。主要终点为大出血联合临床相关非大出血,2.5 mg组发生率为8.9%,5 mg组为12.2%,两组无显著差异(HR 0.72,95%CI 0.38-1.37,P=0.39)。
要点
- 癌症相关VTE患者延长抗凝期间,阿哌沙班2.5 mg每日两次未降低出血事件。
- 阿哌沙班2.5 mg组大出血发生率为2.8%,5 mg组为2.2%,无显著差异。
- 两组复发性VTE或动脉血栓事件发生率均为5.0%,全因死亡率相似。
核心结论
- 对于癌症相关VTE的二级预防,阿哌沙班2.5 mg相比5 mg每日两次并未降低联合出血事件。
研究设计与样本
- 随机双盲试验,纳入已完成6至12个月抗凝治疗的癌症相关VTE患者,比较阿哌沙班2.5 mg与5 mg每日两次治疗12个月。
- 共招募370例患者,其中360例纳入意向性治疗分析。
主要发现
- 大出血联合临床相关非大出血在阿哌沙班2.5 mg组179例中发生16例(8.9%),5 mg组181例中发生22例(12.2%)(HR 0.72;95%CI 0.38-1.37;P=0.39)。
- 大出血在阿哌沙班2.5 mg组发生率为2.8%,5 mg组为2.2%(HR 1.26;95%CI 0.34-4.66;P=0.73)。
- 复发性VTE或动脉血栓在阿哌沙班2.5 mg组179例中发生9例(5.0%),5 mg组181例中发生9例(5.0%)(HR 1.0;95%CI 0.40-2.53;P=1.00)。
- 全因死亡率两组相似,分别为13%与12%(HR 1.14;95%CI 0.63-2.04;P=0.67)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer-associated venous thromboembolism (VTE) management guideline recommendations include continued therapeutic anticoagulation while active cancer persists. The Federal Drug Administration label for apixaban for secondary VTE prevention includes a dose reduction to 2.5 mg twice daily after 6 months of treatment. OBJECTIVES: The study's purpose was to determine whether this dose reduction is advisable for cancer-associated VTE. METHODS: A randomized, double-blind trial compared apixaban 2.5 mg with 5 mg twice daily for 12 months among cancer patients with VTE who had completed 6 to 12 months of anticoagulation therapy. The primary outcome was combined major bleeding plus clinically relevant nonmajor bleeding. RESULTS: Of 370 patients recruited, 360 were included in the intention-to-treat analyses. Major plus clinically relevant nonmajor bleeding occurred in 16 of 179 patients (8.9%) in the apixaban 2.5 mg group compared with 22 of 181 patients (12.2%) in the 5 mg group (hazard ratio [HR], 0.72; 95% CI, 0.38-1.37; P = .39). Major bleeding occurred in 2.8% of the apixaban 2.5 mg group and in 2.2% of the 5 mg group (HR, 1.26; 95% CI, 0.34-4.66; P = .73). Recurrent VTE or arterial thrombosis occurred in 9 of 179 patients (5.0%) in the apixaban 2.5 mg group and 9 of 181 patients (5.0%) in the 5 mg group (HR, 1.0; 95% CI, 0.40-2.53; P = 1.00). All-cause mortality rates were similar between groups, 13% vs 12% (HR, 1.14; 95% CI, 0.63-2.04; P = .67). CONCLUSION: For secondary prevention of cancer-associated VTE, apixaban 2.5 mg compared with 5 mg twice daily did not lower combined bleeding events (EVE trial NCT03080883).
引用
- McBane RD, Loprinzi CL, Zemla T, et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. J Thromb Haemost. 2024. PMID: 38537780. doi:10.1016/j.jtha.2024.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。